32名の方が先月見積もりをリクエストしました
Mustafa Solak
- 5.0 優秀 • 1 レビュー
- 20年の経験
- 所在地: トルコ, イスタンブール
Solak医師は前立腺癌の化学療法を専門とし、ハジェテペ大学癌研究所およびMDアンダーソンがんセンターで研鑽を積んでいます。
- ハジェテペ大学癌研究所にてフェローシップを修了
- テキサス大学MDアンダーソンがんセンターに勤務
- 前立腺癌をはじめとする各種悪性腫瘍の治療に豊富な経験を持つ
- 乳癌、精巣癌、卵巣癌、肺癌、消化器癌を専門とする
- 続きを読む
トルコのトップ前立腺がん化学療法医師と価格を比較。こちらで最適なマッチングを見つけてください
ご要望と予算に基づいて最適な医師を厳選いたします
医学的監修者 Fahad Mawlood
医学編集者・データサイエンティストトップ医師
22
トルコ
レビュー
14000+
実際の患者より
トップ各国の前立腺がん化学療法価格を比較
国をタップしてトップ医師と価格を表示
個別化された治療計画を無料で取得し、最良のオプションを選択してください。コミットメント不要 · サービス料金なし
最初に表示:
32名の方が先月見積もりをリクエストしました
Solak医師は前立腺癌の化学療法を専門とし、ハジェテペ大学癌研究所およびMDアンダーソンがんセンターで研鑽を積んでいます。
55名の方が先月見積もりをリクエストしました
タンルクル医師は前立腺癌の化学療法を専門とし、腫瘍内科学における複数の国際臨床研究に参加しています。
Dr. Sezer Sağlam is a medical oncologist at Gayrettepe Florence Nightingale Hospital in Istanbul. He specializes in gastrointestinal oncology and the treatment of liver cancer. Dr. Sağlam was nominated for the International Best Researcher Award for his work on liver-transplanted patients. He has served as a professor of medical oncology since 2016.
Dr. Abdullah Sakin is a medical oncologist at Medipol Bahçelievler University Hospital in Istanbul. He specializes in treating complex cancers, including lung, breast, and gastrointestinal malignancies. Dr. Sakin previously served as the Head of the Medical Oncology Department at Yüzüncü Yıl University. He also held a leadership role at Prof. Dr. Cemil Taşçıoğlu City Hospital.
44名の方が先月見積もりをリクエストしました
シナン・カラアスラン博士は、乳がん、大腸がん、泌尿生殖器系がんの管理において最高の腫瘍医の一人です。
イェシム・ユルドゥルム教授は、がん免疫療法および分子標的治療を専門とし、80本以上の国際学術論文を発表するとともに、主要な腫瘍学ハンドブックの共著者でもあります。
Şeref Kömürcü教授は、ECFMGおよびESMO認定の医療および乳腺腫瘍学者であり、トルコを拠点に20年以上の実践経験を持っています。硬癌、乳癌、大腸癌、肺癌の治療を専門としています。
癌管理に関する110を超える論文を書いています。
プロフェッサー ネジデット・ユシュケントは、アンカラ大学医学部を卒業しました。彼はアンカラGATA医学校で内科医学のレジデンシー研修を修了しました。彼はアメリカのテキサス州ダラスで医療用腫瘍学および血液学の臨床フェローシップ研修を行いました。トルコで最初の移植を実施した骨髄移植チームに参加しました。異なる時期に、彼はロンドンのウェストミンスター病院 チャリングクロス、ハマースミス、ロイヤル フリー、ユニバーシティ カレッジ 病院で長期間の客員講師を務め、スイスのバーゼル カントン病院でも講義しました。欧州医学腫瘍学会(ESMO)によって主催された試験に合格し、彼はヨーロッパ医学腫瘍学証明書を取得しました。トルコ医学腫瘍学会の7人の創設会員の1人として、プロフェッサー ユシュケントはトルコ腫瘍学グループ(TOG)の創設者でもありました。
学歴
アンカラ大学医学部, アンカラ 1971
GATA 医学校, アンカラ 1979
ワドレー分子医学研究所, グランビル・モートンがん病院, 医療用腫瘍学および血液学のサブスペシャリティ, 1982
GATA 医学校, 医療用腫瘍学クリニック, アンカラ 1984
GATA 医学校, 医療用腫瘍学クリニック, アンカラ 1989
GATA, 医療用腫瘍学および血液学クリニック, イスタンブール 2001
専門分野
Dr. Sezer Saglam is a medical oncologist at Gayrettepe Florence Nightingale Hospital in Istanbul. He specializes in treating gastrointestinal and breast cancers. His research on rectal cancer timing has influenced global treatment protocols. Dr. Saglam develops personalized therapy plans using targeted medicine and precision techniques.
この医師は、乳がん、肺がん、消化器系がんの治療を専門とする腫瘍学者です。現在、医師はIstinye Liv University Hospitalで診療を行っています。<\/p>
多くの著名な機関でのキャリアを持ち、医師はMalatya State Hospitalで内科専門医として、Ankara Oncology Clinicで医師として、Erzurum Regional Training and Research Hospitalの腫瘍学部門のメンバーとして勤務してきました。<\/p>
医師はSelcuk Universityの医学部を卒業し、2016年に准教授の称号を取得しました。<\/p>
Dr. Cemil Bilir is a professor of medical oncology at VM Medical Park Pendik Hospital in Istanbul. He specializes in immunotherapy and chemotherapy for lung, breast, and prostate cancers. A former research fellow at Northeastern University in Boston, he focused on pharmaceutical biotechnology and nanomedicine. Dr. Bilir works at a JCI-accredited facility where academic physicians provide around-the-clock care.
Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at İstinye University, Liv Hospital Topkapı (2025–present). He previously served as Associate Professor and Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital (2023–2025). He was also a Medical Oncologist there (2018–2021).
He has been a member of ASCO and the Turkish Society of Medical Oncology since 2018. He is the author or co-author of 19 peer-reviewed international papers on colon, breast, gastric, pancreatic, lung, thyroid, sarcoma, and colorectal cancers.
Notable works include a multicentre study on stage IIB colon cancer survival (Journal of Chemotherapy). He also studied the De Ritis ratio for lung metastasis in testicular cancer (Current Urology). His prognostic studies used PET/CT, MSI, lymph node ratio, and metabolic tumor volume.
Dr. Ercan Ozden is a medical oncologist and internal medicine specialist at VM Medical Park Pendik. He provides treatment for a wide range of cancers, including breast, lung, and colon cancer. Dr. Ozden trained at Istanbul University, Cerrahpasa Faculty of Medicine. He later completed a medical oncology subspecialty at Kocaeli University.
Dr. Nail Paksoy is an associate professor of medical oncology at Medipol Bahçelievler Hospital. He is board-certified by the European Society for Medical Oncology (ESMO). Dr. Paksoy specializes in lung, breast, and gastrointestinal cancers. He uses modern immunotherapy and targeted therapy protocols. His clinic is JCI-accredited for high safety standards.
Dr. Mustafa Serkan Alemdar is a clinical oncologist at Medical Park Antalya Hospital Complex. He specializes in treating complex solid tumors and blood cancers. Dr. Alemdar completed his medical degree and oncology fellowship at Akdeniz University. He is an active member of the Turkish Society of Medical Oncology.
Dr. Irfan Cicin is a Professor of Medical Oncology at the Trakya University Faculty of Medicine (2015–present). He has over 20 years of medical oncology experience and has held academic roles since 2010.
Education: MD, Istanbul University – Cerrahpaşa (1991–1997). Residency in Internal Medicine, Trakya University (1997–2002). Fellowship in Medical Oncology, Trakya University (2002–2004).
Practice: Medical Oncologist, Trakya University (2005–2008). Medical Oncologist, Elazığ Training and Research Hospital (2008–2010). Associate Professor of Medical Oncology, Trakya University (2010–2015). He previously served as a physician in the Turkish Air Force at Etimesgut Military Hospital (2004–2005).
Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.
He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.
Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.
Assoc. Prof. Ayşe İrem Yasin, M.D., is a medical oncologist who specializes in solid tumors. Her clinical focus includes breast, lung, gastrointestinal, gynecologic, and urologic cancers. She also treats brain and other CNS tumors, soft tissue sarcomas, head and neck cancers, adenocarcinomas, melanoma, Merkel cell carcinoma, and cancers of unknown primary. She practices at Medipol Acıbadem District Hospital (2025–present). She previously worked at Şişli Etfal Training and Research Hospital (2023–2025).
She completed a Medical Oncology fellowship at Bezmialem Vakıf University (2019–2022). This followed an Internal Medicine residency at the same institution (2012–2016). Her international experience includes the Breast Cancer Unit at the University of Piemonte Orientale in Novara (2022). She also trained at Basel University Hospital, Cleveland Clinic, and Harvard Medical School. She holds the ESMO Board Certificate (2022).
Uzm. Dr. Erkan Göcen is a Radiation Oncology Specialist at Çerkezköy Private Optimed Hospital (Optimed Health Group). He graduated from İstanbul University, İstanbul Faculty of Medicine (Çapa) in 2003.
Career: He trained and practiced in Radiation Oncology from 2010 to 2012. He worked in public and private health institutions from 2012 to 2016. He served in the private medical sector as a Radiation Oncology Specialist from 2016 to 2023. He has been at Optimed Hospital since 2024.
Clinical interests: cancers of the brain, head and neck, esophagus, stomach, colorectal, pancreas, prostate, bladder, lung, soft tissues (sarcomas), skin, uterus and cervix, and breast. Affiliations: Turkish Society for Radiation Oncology (TROD) and Tekirdağ Medical Chamber. Languages: English and Turkish.
22名の医師のうち20名をご覧いただきました
海外のクリニックを選ぶことはストレスフルです。800,000名以上の患者をサポートしたBookimedは、お客様の懸念を理解しています。信頼できる医師、最高の価格品質オプション、複雑なケースの解決策を見つける方法を知っています。すべての段階でお客様をご案内いたします。
ヤン・マツィイフスキー
医療コーディネーターチーム責任者
4300+件以上の患者の旅をガイド
Bookimedで3年
Turkeyの278名の患者が今月当社を通じて医師を見つけました
2分のクイズ
目標、予算、スケジュールをお聞かせください
人間のマッチング + AI
アルゴリズムがマッチングを見つけ、コーディネーターが適合性を確認します
オプション準備完了
価格、パッケージ、日程を比較。コーディネーターとチャット
選択肢に迷っていますか?
治療をガイド
医療訓練を受けた専属コーディネーター






| 順位 | 医師 | 経験 | 適合する方 | 特色 | クリニックと所在地 | 診察 |
|---|---|---|---|---|---|---|
| #1 | 20年の経験 | 前立腺癌化学療法 | ハジェテペ大学癌研究所およびMDアンダーソンがんセンターにて専門研修を修了。前立腺癌を中心に、さまざまな癌の治療に豊富な経験を有する。 | トルコ | から $100 | |
| #2 | 21年の経験 | 前立腺癌化学療法 | 前立腺癌に対する化学療法プロトコルを専門とする。トルコの腫瘍学試験で3位を獲得し、腫瘍内科ユニットを主導した。 | トルコ | から $215 | |
| #3 | 22年の経験 | 分子標的治療薬 | 免疫療法および精密医療の専門家として、『Handbook of Advanced Cancer Care Treatment』を共著。ESMOの認定資格を有し、イスラエルおよび英国にて高度な研修を修了。 | トルコ | から $215 |
Top medical oncologists in Turkey for prostate cancer hold certifications from the European Society for Medical Oncology (ESMO). Specialists like Dr. Mustafa Solak and Dr. Yesim Yildirim treat advanced cases at JCI-accredited centers. These doctors often have training from MD Anderson or Rambam Medical Center.
Bookimed Expert Insight: Data shows a high concentration of urological cancer specialists at Anadolu Medical Center. Dr. Eda Tanrikulu ranked 3rd in Turkey's national oncology exam, highlighting the competitive academic rigor. Patients can access consultations with these experts starting from $100 to around $215.
Patient Consensus: Patients note that getting a second opinion on pathology is vital before starting chemotherapy. They appreciate oncologists who are direct about side effects like fatigue or neuropathy. Many felt more confident when their doctor personally managed complex sequencing for metastatic cases.
Turkish prostate cancer specialists must hold a Medical Oncology Specialty License after completing a specific internal medicine residency and a three-year oncology fellowship. Look for professors with ESMO certification and international training from institutions like MD Anderson or Cleveland Clinic.
Bookimed Expert Insight: Data shows that leading Turkish oncologists often hold dual certifications and international research background. For instance, Dr. Yesim Yildirim and Dr. Seref Komurcu are both ESMO-certified with over 20 years of experience. Dr. Cemil Bilir and Dr. Mustafa Solak gained expertise at prestigious US institutions like the Cleveland Clinic and MD Anderson, offering patients access to global treatment protocols in Istanbul.
Patient Consensus: Patients note it is important to find an oncologist who explains hormone and chemotherapy sequencing in plain language. Many emphasize choosing a specialist at hospitals with tumor boards to ensure all doctors coordinate the treatment plan together. Families often feel relieved when the doctor has specific experience managing side effects for advanced cancer cases.
Turkey's top specialists in prostate cancer chemotherapy practice at JCI-accredited centers in Istanbul and Antalya. These institutions feature multidisciplinary tumor boards and ESMO-certified departments. Leading oncologists hold fellowships from institutions like MD Anderson and the Cleveland Clinic to manage complex systemic treatments.
Bookimed Expert Insight: Data shows a strong trend of international training among Turkey's medical oncology leaders. For instance, Dr. Mustafa Solak and Dr. Cemil Bilir trained at top-tier US institutions like MD Anderson and the Cleveland Clinic. This exposure allows them to implement the latest global chemotherapy sequencing for aggressive, castration-resistant cases.
Patient Consensus: Patients emphasize that successful treatment depends on choosing hospitals with in-house PSMA PET-CT and pathology labs. They note that having all diagnostics under one roof prevents delays in starting chemotherapy cycles. Many were relieved to find that major centers provide English-speaking coordinators to explain each step of the plan.